Outcomes of HCV treatment: Who does well and who does not?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 5, 2010, Pages 846-848

  Hsu, Ching Sheng ^a,b   Kao, Jia Horng ^b,c  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INTERFERON; INTERLEUKIN 28; PEGINTERFERON; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT; INTERLEUKIN 28B;

ACCURACY; AMINO ACID SUBSTITUTION; ANALYTIC METHOD; ANTIVIRAL THERAPY; CANCER RISK; CHRONIC HEPATITIS; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; EDITORIAL; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HUMAN; IMMUNOTHERAPY; INSULIN RESISTANCE; LIVER BIOPSY; LIVER FIBROSIS; LIVER STIFFNESS; PATIENT COMPLIANCE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS HEPATITIS; VIRUS LOAD; BLOOD; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER; LIVER CIRRHOSIS; PATHOLOGY; PATIENT SELECTION; RECURRENT DISEASE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME; VIROLOGY; AGE; ALGORITHM; AMINOTRANSFERASE BLOOD LEVEL; ASIAN; BODY MASS; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; CLINICAL PRACTICE; ELASTOGRAPHY; ETHNICITY; GOLD STANDARD; HEALTH CARE QUALITY; HEPATITIS C VIRUS GENOTYPE 1; LIVER HISTOLOGY; PERSONALIZED MEDICINE; PROGNOSIS;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; PATIENT SELECTION; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; RNA, VIRAL; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77951745893     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06278.x     Document Type: Editorial

References (19)

1. Kao JH, Chen DS. Transmission of hepatitis C virus in Asia: past and present perspectives. J. Gastroenterol. Hepatol. 2000 15 (Suppl E91 6.
2. Liu CH, Liu CJ, Lin CL et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin. Infect. Dis. 2008 47 : 1260 1269.
3. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J. Gastroenterol. Hepatol. 2009 24 : 336 345.
4. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004 39 : 1147 1171.
5. Hsu CS, Liu CH, Liu CJ et al. Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. Antivir. Ther. 2009 14 : 45 54.
6. Berg T, Sarrazin C, Herrmann E et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003 37 : 600 609.
7. Shin SR, Sinn DH, Gwak G-Y et al. Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response. J. Gastroenterol. Hepatol. 2010 25 : 957 963.
8. Wang J-H, Changchien C-S, Hung C-H et al. Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study using FibroScan. J. Gastroenterol. Hepatol. 2010 25 : 964 969.
9. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009 49 : 1335 1374.
10. Jacobson IM, Brown RS, Jr., Freilich B et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007 46 : 971 981.
11. Basso M, Giannini EG, Torre F, Blanchi S, Savarino V, Picciotto A. Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse. Hepatology 2009 49 : 1442 1448.
12. Malik R, Afdhal N. Stiffness and impedance: the new liver biomarkers. Clin. Gastroenterol. Hepatol. 2007 5 : 1144 1146.
13. Liu CH, Hsu SJ, Lin JW et al. Noninvasive diagnosis of hepatic fibrosis in patients with chronic hepatitis C by splenic Doppler impedance index. Clin. Gastroenterol. Hepatol. 2007 5 : 1199 1206 e1.
14. Shiratori Y, Imazeki F, Moriyama M et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann. Intern. Med. 2000 132 : 517 524.
15. Arena U, Vizzutti F, Corti G et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008 47 : 380 384.
16. Wong GL, Wong VW, Choi PC et al. Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. J. Gastroenterol. Hepatol. 2009 24 : 1002 1007.
17. Chan HL, Wong GL, Choi PC et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J. Viral Hepat. 2009 16 : 36 44.
18. Akuta N, Suzuki F, Kawamura Y et al. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology 2007 46 : 1357 1364.
19. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009 461 : 399 401.